Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
Key Highlights
- ➤FDA issues Complete Response Letter for Deramiocel’s resubmitted DMD BLA
- ➤FDA says data insufficient to establish substantial evidence of effectiveness
- ➤Capricor had approximately $198.5 million in cash and securities at September 30
- ➤Company says funds support planned operations for at least the next 12 months
- ➤Capricor reviewing operating costs to extend its cash runway
Expert Statements
Linda Marbán, Chief Executive Officer of Capricor Therapeutics
“We are deeply disappointed for the boys and young men living with Duchenne and their families.”
Linda Marbán, Chief Executive Officer of Capricor Therapeutics
“Deramiocel has been studied in two randomized, double-blind, placebo-controlled trials, HOPE-2 and HOPE-3, both of which met their primary endpoints.”
Linda Marbán, Chief Executive Officer of Capricor Therapeutics
“We stand behind the rigor of our clinical program and the integrity of our data, and we believe the data support approval.”
Linda Marbán, Chief Executive Officer of Capricor Therapeutics
“We are reviewing the letter carefully and will share next steps once we have completed our evaluation.”
* Company receives Complete Response Letter from FDA for Deramiocel BLA * Conference call and webcast Monday, November 23, at 8:30 a.m. ET SAN DIEGO, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its resubmitted Biologics License Application (BLA) for Deramiocel, its investigational cell therapy for Duchenne muscular dystrophy (DMD). The CRL states that the FDA does not consider the data sufficient to establish substantial evidence of effectiveness and cites certain other clinical deficiencies.
“We are deeply disappointed for the boys and young men living with Duchenne and their families,” said Linda Marbán, Ph.D., Capricor’s Chief Executive Officer. “Deramiocel has been studied in two randomized, double-blind, placebo-controlled trials, HOPE-2 and HOPE-3, both of which met their primary endpoints. We stand behind the rigor of our clinical program and the integrity of our data, and we believe the data support approval. We are reviewing the letter carefully and will share next steps once we have completed our evaluation.”
Get started
Create a free account to read the full story.
